Unique ID issued by UMIN | UMIN000001422 |
---|---|
Receipt number | R000001694 |
Scientific Title | Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder |
Date of disclosure of the study information | 2008/10/14 |
Last modified on | 2011/10/07 17:25:52 |
Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder
Botulinum toxin injection in non-neurogenic OAB
Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder
Botulinum toxin injection in non-neurogenic OAB
Japan |
Non-neurogenic overactive bladder
Urology |
Others
NO
To evaluate effect and safety of subepithelial injection of Botulinum toxin A for patients with refractory non-neurogenic overactive bladder
Safety,Efficacy
Change of the number of urge urinary incontinence 1month after treatment
Recurrence of urge urinary incontinence, change of bladder capacity and symptoms after treatment
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
After solving Botulinum toxin A 100 units by normal saline 15ml, 30 subepithelial injections avoiding injection into trigone are performed.
20 | years-old | <= |
Not applicable |
Male and Female
1) Patient has non-neurogenic overactive bladder.
2) Written informd consent is required.
3) One or more times a week of urge urinary incontinence was seen after antichorinergic drugs or antichorinergic drugs could not be continued because of adverse effects.
1) The patient has apparent neurogenic diseases causing urinary tract symptoms.
2) The patient underwent treatment with botulinum toxin A.
3) The patient underwent the surgery of lower urinary tract within 1 year.
4) Postvoid residual urine is 100ml or greater.
5) The patient has apparent lower urinary tract obstruction and/or weak detrusor.
6) Average voiding volume are 200ml or greater on frequency-volume chart.
7) The patient has stress urinary incontinence and/or functional urinary incontinence.
8) The patient has active urinary tract infection, malignance and/or bladder stone.
9) The patient is pregnant or breast-feed, or have possibility of such matter within 1 year.
10) The patient is diagnosed as having myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis.
11) The patient has disturbance of swallowing and/or respiration.
12) The patitent has mental and/or cognitive disturbance to conduct the clinical trial.
13) The patient is judged as being unsuitable for the trial by the researcher.
45
1st name | |
Middle name | |
Last name | Kikuo Okamura |
National Center for Geriatrics & Gerontology
Division of Urology, Department of Surgery & Intensive Care
36-3, Gengo Morioka-cho Obu Aichi, Japan
0562-46-2311
1st name | |
Middle name | |
Last name | Kikuo Okamura |
National Center for Geriatrics & Gerontology
Division of Urology, Department of Surgery & Intensive Care
36-3, Gengo, Morioka-cho Obu Aichi, Japan
0562-46-2311
kokamura@ncgg.go.jp
National Center for Geriatrics & Gerontology
Ministry of Health, Labour and Welfare,Japan
Japan
Tokyo University
Nagoya University
NO
2008 | Year | 10 | Month | 14 | Day |
Partially published
No longer recruiting
2008 | Year | 03 | Month | 24 | Day |
2008 | Year | 06 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 09 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2008 | Year | 10 | Month | 09 | Day |
2011 | Year | 10 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001694